AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34170389 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF asparagine depletion
Number of subjects: 482
Study 32949650 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 279
Study 35426136 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 60
Study 35426136 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 100 mg
Number of subjects: 60
Study 35426136 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 60
Study 35426136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35426136 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant (both doses)
Number of subjects: 60
Study 35426136 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant
Number of subjects: 60
Study 34171555 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (verum group)
Number of subjects: 181
Study 34171555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 181
Study 34232704 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaking fundamental frequency (fos)
Number of subjects: 379
Study 34232704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vowel formant frequencies (F1, F2, F3)
Number of subjects: 379
Study 34232704 — intervention group
Group type: COMPARATOR
Intervention: Listener perceptions of speaker gender
Number of subjects: 379
Study 36295519 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intramuscular vitamin D (cholecalciferol 200,000 IU)
Number of subjects: 116
Study 36295519 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (alfacalcidol 1 mcg/day)
Number of subjects: 116
Study 33468283 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally focused nutrition education intervention (weekly sessions for 12 weeks)
Number of subjects: 498
Study 33468283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sessions conducted)
Number of subjects: 498
Study 33468283 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally focused nutrition education intervention
Number of subjects: 498
Study 32327729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 489
Study 32327729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 32327729 — intervention group
Group type: EXPERIMENTAL
Intervention: Deepening responses (Ixazomib)
Number of subjects: 489
Study 32327729 — intervention group
Group type: COMPARATOR
Intervention: Deepening responses (Placebo)
Number of subjects: 489
Study 32327729 — intervention group
Group type: EXPERIMENTAL
Intervention: Without deepening responses (Ixazomib)
Number of subjects: 489
Study 32327729 — intervention group
Group type: COMPARATOR
Intervention: Without deepening responses (Placebo)
Number of subjects: 489
Study 33355028 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) plus usual care
Number of subjects: 411
Study 33355028 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 411
Study 33990993 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-cancer drugs
Number of subjects: 0
Study 33990993 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard therapies
Number of subjects: 0
Study 32241810 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL/kg/day feed advancement
Number of subjects: 2468
Study 32241810 — intervention group
Group type: COMPARATOR
Intervention: 18 mL/kg/day feed advancement (control)
Number of subjects: 2468
Study 36217901 — intervention group
Group type: COMPARATOR
Intervention: RP7214 single dose (100, 200, and 400 mg QD)
Number of subjects: 42
Study 36217901 — intervention group
Group type: COMPARATOR
Intervention: RP7214 multiple doses (200 and 400 mg BID for 7 days)
Number of subjects: 42
Study 36217901 — intervention group
Group type: COMPARATOR
Intervention: RP7214 single dose (200 mg) food effect study
Number of subjects: 42
Study 33172305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolstered standard of care plus family economic empowerment intervention
Number of subjects: 702
Study 33172305 — intervention group
Group type: COMPARATOR
Intervention: Bolstered standard of care
Number of subjects: 702
Study 34887236 — intervention group
Group type: EXPERIMENTAL
Intervention: FPBB+LLLT
Number of subjects: 42
Study 34887236 — intervention group
Group type: COMPARATOR
Intervention: UCG
Number of subjects: 42
Study 33714796 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV infection cohort
Number of subjects: 30001
Study 33714796 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (patients without HPV infection)
Number of subjects: 30001
Study 32694454 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Cardiac Rehabilitation (CCR)
Number of subjects: 115
Study 32694454 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only CR
Number of subjects: 115
Study 32694454 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 115
Study 36463269 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint nomogram incorporating clinical factors and radiomic signature
Number of subjects: 299
Study 36463269 — intervention group
Group type: COMPARATOR
Intervention: Clinical nomogram
Number of subjects: 299
Study 36463269 — intervention group
Group type: COMPARATOR
Intervention: Radiomics predictive models
Number of subjects: 299
Study 36463269 — intervention group
Group type: COMPARATOR
Intervention: Joint nomogram vs Clinical nomogram
Number of subjects: 299
Study 32993380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL (iPure, PhysIOL)
Number of subjects: 31
Study 32993380 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic acrylic control IOL (Tecnis ZCB00, Johnson&Johnson)
Number of subjects: 31
Study 36395131 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 15
Study 36395131 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study 34192893 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg for 3.3 years
Number of subjects: 8580
Study 34192893 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen for 5.5 years
Number of subjects: 8580
Study 34192893 — intervention group
Group type: EXPERIMENTAL
Intervention: BP variability (SD mean BP)
Number of subjects: 8580
Study 33067624 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA epitope‐matched (HEM) platelets
Number of subjects: 49
Study 33067624 — intervention group
Group type: COMPARATOR
Intervention: HLA standard antigen‐matched (HSM) platelets
Number of subjects: 49
Study 34724457 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 118
Study 34724457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 36011699 — intervention group
Group type: EXPERIMENTAL
Intervention: Packaged operation and maintenance interventions in Roxas City schools
Number of subjects: 30
Study 36011699 — intervention group
Group type: COMPARATOR
Intervention: Control group in Passi City schools
Number of subjects: 30
Study 32979877 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% autogenous bone (AB)
Number of subjects: 30
Study 32979877 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% deproteinized bovine bone matrix (DBBM)/ 50% autogenous bone (BOAB)
Number of subjects: 30
Study 35106590 — intervention group
Group type: EXPERIMENTAL
Intervention: HP501 (45 mg) administered over 10 days to hyperuricemic patients
Number of subjects: 100
Study 35106590 — intervention group
Group type: EXPERIMENTAL
Intervention: HP501 (doses from 5 to 60 mg)
Number of subjects: 100
Study 35106590 — intervention group
Group type: EXPERIMENTAL
Intervention: HP501 and febuxostat combination
Number of subjects: 100
Study 35507345 — intervention group
Group type: EXPERIMENTAL
Intervention: EPICC (Empowering Patients in Chronic Care) intervention, which included 6 group sessions and individual motivational interviewing sessions.
Number of subjects: 280
Study 35507345 — intervention group
Group type: EXPERIMENTAL
Intervention: EPICC (Empowering Patients in Chronic Care) intervention during maintenance phase.
Number of subjects: 280
Study 35507345 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) with diabetes education.
Number of subjects: 280
Study 32532249 — intervention group
Group type: EXPERIMENTAL
Intervention: HABIT‐ILE (50 hours over 2 weeks)
Number of subjects: 50
Study 32532249 — intervention group
Group type: COMPARATOR
Intervention: Regular motor activity and/or customary rehabilitation
Number of subjects: 50
Study 35106827 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anticoagulant therapy in patients with AF
Number of subjects: 260
Study 35106827 — intervention group
Group type: EXPERIMENTAL
Intervention: AF duration > 3 years
Number of subjects: 260
Study 35106827 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosome concentrations of T-tau and Aβ42 in the CI group
Number of subjects: 260
Study 35106827 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of IL-6 and MMP-9 in patients with AF
Number of subjects: 260
Study 33475958 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for single cell clustering using UMAP and k-means algorithm
Number of subjects: 0
Study 33475958 — intervention group
Group type: COMPARATOR
Intervention: Control method not specified
Number of subjects: 0
Study 32152642 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training + whey protein isolate
Number of subjects: 37
Study 32152642 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic eccentric training
Number of subjects: 37
Study 33106609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin treatment
Number of subjects: 157
Study 33106609 — intervention group
Group type: COMPARATOR
Intervention: Standard statin treatment
Number of subjects: 157
Study 32990012 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision mesh (MESH)
Number of subjects: 146
Study 32990012 — intervention group
Group type: COMPARATOR
Intervention: Sacrospinous ligament fixation (ACSSF)
Number of subjects: 146
Study 35857716 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine Extended-Release Tablets (AMPH ER TAB) 5 mg starting dose, increased to 20 mg for 14±3 days before visit 5.
Number of subjects: 130
Study 35857716 — intervention group
Group type: COMPARATOR
Intervention: Placebo, matching the AMPH ER TAB.
Number of subjects: 130
Study 33956056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapirolizumab pegol (DZP) 6/24/45 mg/kg
Number of subjects: 0
Study 33956056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33956056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapirolizumab pegol (DZP)
Number of subjects: 0
Study 33272291 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 63
Study 33272291 — intervention group
Group type: COMPARATOR
Intervention: non-COVID-19 patients
Number of subjects: 63
Study 34474447 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and arthroplasty (ACDA)
Number of subjects: 251
Study 34474447 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 251
Study 34474447 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy (ACD)
Number of subjects: 251
Study 32340597 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-supported care
Number of subjects: 859
Study 32340597 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed care
Number of subjects: 859
Study 35737687 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) telephone coaching intervention
Number of subjects: 120
Study 35737687 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 34107772 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser plus DCB
Number of subjects: 61
Study 34107772 — intervention group
Group type: COMPARATOR
Intervention: Control (POBA)
Number of subjects: 61
Study 32995892 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (EX) 10-20μg daily
Number of subjects: 150
Study 32995892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (COM) of Exenatide and Metformin
Number of subjects: 150
Study 32995892 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) 1500-2000 mg daily
Number of subjects: 150
Study 32048890 — intervention group
Group type: EXPERIMENTAL
Intervention: RIBSP vaccine
Number of subjects: 150
Study 32048890 — intervention group
Group type: COMPARATOR
Intervention: VAXIGRIP® vaccine
Number of subjects: 150
Study 35155345 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentorship as an intervention to address workplace hazards
Number of subjects: 19
Study 35155345 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study 33096665 — intervention group
Group type: EXPERIMENTAL
Intervention: Air purifiers with filter on
Number of subjects: 26
Study 33096665 — intervention group
Group type: COMPARATOR
Intervention: Air purifiers with filter off
Number of subjects: 26
Study 35910353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin/albendazole 18/400 mg (1 tablet)
Number of subjects: 78
Study 35910353 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin 3 mg (6 tablets)
Number of subjects: 78
Study 35910353 — intervention group
Group type: COMPARATOR
Intervention: Albendazole 400 mg (1 tablet)
Number of subjects: 78
Study 35165297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate (FC)
Number of subjects: 82
Study 35165297 — intervention group
Group type: COMPARATOR
Intervention: Non-iron-based phosphate binders (Control)
Number of subjects: 82
Study 35005202 — intervention group
Group type: EXPERIMENTAL
Intervention: Application‐based Cognitive Training at Home (ACTH) for 12 months
Number of subjects: 389
Study 35005202 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 389
Study 32705834 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with moxibustion
Number of subjects: 60
Study 32705834 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Jingui Shenqi pills and Suoquan capsules
Number of subjects: 60
Study 34515619 — intervention group
Group type: EXPERIMENTAL
Intervention: Yakson
Number of subjects: 90
Study 34515619 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle human touch
Number of subjects: 90
Study 34515619 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 32440738 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (n=41)
Number of subjects: 92
Study 32440738 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=51)
Number of subjects: 92
Study 32440738 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 92
Study 36297036 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of p-synephrine
Number of subjects: 18
Study 36297036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 18
Study 33551687 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Simple Reaction Time (SRT) measured at three different times of the day (10 a.m., 1 p.m., and 5 p.m.)
Number of subjects: 20
Study 34614121 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.018-inch NiTi archwire
Number of subjects: 40
Study 34614121 — intervention group
Group type: COMPARATOR
Intervention: 0.014-inch NiTi archwire
Number of subjects: 40
Study 34614121 — intervention group
Group type: COMPARATOR
Intervention: 0.016-inch NiTi archwire
Number of subjects: 40
Study 32960999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder Training (BT) + Electrical Stimulation (ES)
Number of subjects: 70
Study 32960999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder Training (BT) + Biofeedback (BF) + Electrical Stimulation (ES)
Number of subjects: 70
Study 32960999 — intervention group
Group type: COMPARATOR
Intervention: Bladder Training (BT) + Biofeedback (BF)
Number of subjects: 70
Study 32960999 — intervention group
Group type: COMPARATOR
Intervention: Bladder Training (BT) alone
Number of subjects: 70
Study 34407575 — intervention group
Group type: EXPERIMENTAL
Intervention: Licofor
Number of subjects: 60
Study 34407575 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study 36350349 — intervention group
Group type: EXPERIMENTAL
Intervention: empowerED
Number of subjects: 100
Study 36350349 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 34406598 — intervention group
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB)
Number of subjects: 80
Study 34406598 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 80
Study 33390295 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine approval announced one week before the presidential election
Number of subjects: 0
Study 33390295 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccine approval announced one week after the presidential election
Number of subjects: 0
Study 33390295 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement by Dr. Anthony Fauci
Number of subjects: 0
Study 33390295 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement by Dr. Anthony Fauci with pre-election vaccine approval
Number of subjects: 0
Study 33389320 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral pre-exposure prophylaxis and adherence support
Number of subjects: 193
Study 35334049 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated acid rain (pH 5.0, 4.0, and 3.0)
Number of subjects: 3
Study 35334049 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (pH 6.0)
Number of subjects: 3
Study 35334049 — intervention group
Group type: EXPERIMENTAL
Intervention: Brassica rapa (at pH 3.0)
Number of subjects: 3
Study 33719503 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech Intelligibility Treatment (SIT)
Number of subjects: 10
Study 33719503 — intervention group
Group type: COMPARATOR
Intervention: Hand‐Arm Bimanual Intensive Therapy Including Lower Extremities (PT)
Number of subjects: 10
Study 32343977 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux ablation therapy (ARAT)
Number of subjects: 108
Study 35961933 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 50
Study 35961933 — intervention group
Group type: COMPARATOR
Intervention: Desktop Interfaces (DI)
Number of subjects: 50
Study 32525464 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized blood pressure lowering treatment
Number of subjects: 483
Study 32525464 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure lowering treatment
Number of subjects: 483
Study 32417382 — intervention group
Group type: COMPARATOR
Intervention: IV Lorazepam (LZP)
Number of subjects: 46
Study 32417382 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Brivaracetam 100 mg
Number of subjects: 46
Study 32417382 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Brivaracetam 200 mg
Number of subjects: 46
Study 35352835 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg Q4W
Number of subjects: 819
Study 35352835 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 150 mg Q4W
Number of subjects: 819
Study 35352835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 819
Study 34782024 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-based upper-limb reaching task with robot-generated haptic guidance and audio-visual feedback
Number of subjects: 30
Study 34782024 — intervention group
Group type: COMPARATOR
Intervention: Control group with similar robotic training but without vision occluded and robot-generated cues
Number of subjects: 30
Study 34125340 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-dkst
Number of subjects: 242
Study 34125340 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 242
Study 33496122 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formula (CHMF)
Number of subjects: 41
Study 36317791 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitogel
Number of subjects: 82
Study 36317791 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitogel + Def + GaPP
Number of subjects: 82
Study 36317791 — intervention group
Group type: COMPARATOR
Intervention: No packing (control)
Number of subjects: 82
Study 32072468 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal test and treat (UTT) approach
Number of subjects: 0
Study 32072468 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded provision of ART
Number of subjects: 0
Study 32072468 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 35815898 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 2062
Study 35815898 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 2062
Study 34215216 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) treatment for 12 weeks (transcranial, intranasal, neck and abdominal)
Number of subjects: 12
Study 34215216 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment with PBM devices after initial 12 weeks
Number of subjects: 12
Study 34215216 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group (6 participants)
Number of subjects: 12
Study 32867954 — intervention group
Group type: EXPERIMENTAL
Intervention: 29°C
Number of subjects: 144
Study 32867954 — intervention group
Group type: EXPERIMENTAL
Intervention: 32°C
Number of subjects: 144
Study 32867954 — intervention group
Group type: EXPERIMENTAL
Intervention: 35°C
Number of subjects: 144
Study 32867954 — intervention group
Group type: COMPARATOR
Intervention: 26°C (control)
Number of subjects: 144
Study 34216265 — intervention group
Group type: EXPERIMENTAL
Intervention: MHD patients with MSFB
Number of subjects: 60
Study 34216265 — intervention group
Group type: COMPARATOR
Intervention: Non-MHD patients with MSFB
Number of subjects: 60
Study 34216265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MHD and non-MHD)
Number of subjects: 60
Study 33001564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental floss with soft ellipsoidal knots
Number of subjects: 33
Study 33001564 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental floss
Number of subjects: 33